The Latest Cardiac and Vascular News
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat in […]
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share […]
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am ET, to correct and clarify certain information contained […]
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension Completed enrollment in the HALO Phase 2 trial for baxdrostat in patients with uncontrolled hypertension with […]
Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for uncontrolled hypertension (uHTN) expected in 2H 2022 Phase 2 figHTN-CKD trial […]
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. named Chief Medical […]
BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee brings decades of leadership experience in the biotechnology and […]
CINCINNATI, Oct. 28, 2021 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Terry Coelho as Executive Vice President, Chief Financial Officer and Chief Business Development Officer (EVP, CFO and CBDO). “Terry gained broad financial and operational […]
CINCINNATI, Oct. 19, 2021 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Mason W. Freeman, M.D., as Executive Vice President, Clinical Development responsible for leading all clinical development at CinCor. “Mason will be guiding the clinical […]
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study. The brigHTN study is a Phase 2 […]
